Making of a Modern Drug Hunter: Meet Sharath Hegde, Chief Scientific Officer at Congruence

Drug discovery can seem, at first, like a pursuit of science alone. Yet, over time, it reveals itself to be something more. It is a discipline built on patience and precision, where knowledge must withstand doubt before it can be trusted. And when it does, it becomes more than discovery; it becomes the foundation of healing.

A career in medicine for Sharath Hegde did not begin with certainty. It began with absence.

He grew up in Chembur, in Mumbai, in an environment where ambition often takes recognisable forms. Like many drawn to science, he wanted to become a physician, to treat patients directly, to be present at the point where illness meets care. But that path closed abruptly. He missed admission to medical school by two points. It was a small difference in number, but not in consequence. As he describes it plainly, “it created a deep void in me.”

He turned instead toward pharmacology.

He entered pharmacy school and began studying it, and in that process realized that his curiosity did not lie in treating patients directly, but in understanding and discovering the treatments that could heal them. If medicine responds to illness, pharmacology seeks to create the response itself. It is not a departure from healing, but a movement toward the science that makes healing possible.

This perspective stayed with him.

He pursued his Master’s at UDCT, now the Institute of Chemical Technology, where his training became more rigorous, more exacting. The questions grew more complex, and the answers less immediate. Science, he learned, demands patience. It asks for a willingness to remain with uncertainty longer than is comfortable.

That path led him to the United States, to the University of Houston, where he completed his PhD in pharmacology, formally entering the world of drug discovery.

It is a field often misunderstood from the outside.

Drug discovery is not a sequence of breakthroughs, but a long engagement with uncertainty. It is one of the most regulated industries in the world, where every molecule must prove not only that it works, but that it is safe, reproducible, and meaningful at scale. Many spend entire lifetimes within this discipline and have little to show in terms of final, approved outcomes.

When asked about his own success, he does not attribute it solely to ability or effort. Instead, he attributes it to luck. As he puts it, “right drug, right environment.” It is his way of acknowledging that even in a field defined by rigor, there are elements that cannot be fully controlled.

And yet, he has been among the few.

Sharath Hegde with a patient, whose life was saved by the antibiotic telavancin, which he helped discover

Over a career spanning more than three decades, he has worked across an extraordinary range of therapeutic areas, from infectious diseases and cancer to neuroscience, immunology, and cardiometabolic conditions . This breadth reflects not only expertise, but an ability to move between systems, to understand how biology expresses itself differently across diseases and patient populations.

He has been part of the discovery and development of three marketed medicines, including VIBATIV® (telavancin), YUPELRI™ (revefenacin), and ALOXI® (palonosetron), each addressing serious and often complex clinical conditions . Beyond these, he has contributed to the discovery of multiple additional compounds that have advanced into late-stage clinical trials, a rare and significant outcome in a field where most research never reaches patients.

His work sits at the intersection of science and execution. It is not only about identifying promising molecules, but about guiding them through the long and exacting process of validation. This includes everything from pharmacokinetics and translational biology to the regulatory frameworks that determine how drugs move from laboratory to clinic. It is a discipline that demands both depth and coordination, an ability to think at the molecular level while operating within systems that span continents.

Across institutions such as Roche, Theravance Biopharma, Recursion Pharmaceuticals, and now Congruence Therapeutics, he has led multidisciplinary teams of chemists, biologists, computer and data scientists, often at the frontier of integrating biology with emerging technologies such as machine learning. His work reflects a field that continues to evolve, even as its core challenges remain unchanged.

Alongside this, his academic contributions remain substantial. With more than sixty-five peer-reviewed publications, he has contributed to the scientific foundation that underpins modern pharmacology, ensuring that knowledge is not only applied but extended.

Externally, he has come to be described as a “drug hunter,” a term reserved for those who operate at the frontier of therapeutic discovery, combining scientific rigor with the ability to translate ideas into real-world treatments. It is a role that demands not only expertise but endurance, an ability to remain committed in a field where success is rare and often delayed.

But the meaning of this work, for him, is not contained in titles or recognition.

When asked whether it was a humbling experience to see medicines he helped create reach patients, he paused, searching for language that could hold the weight of the moment. There was joy, certainly, in seeing a molecule move from concept to care. But there was also something quieter, more difficult to articulate. The awareness that somewhere, a patient’s life had changed because of work he had been part of. That the distance between laboratory and life had, in that moment, been bridged.

It is both joyful and humbling, inseparable in its meaning.

Outside the laboratory, his life moves to a different rhythm. He hikes, drawn to landscapes that stand in contrast to the controlled precision of scientific work. There is something in that movement, the unpredictability of terrain, the steady progress over time, that mirrors, in its own way, the nature of his profession.

He also collects antique medicine bottles, some dating back to the 1800s. They are small, quiet artefacts, reminders of a much earlier era of medicine, a time when treatments were less precise, less understood, and often uncertain. In collecting them, there is a quiet acknowledgement that modern discovery is part of a much longer continuum, one built through generations of inquiry and persistence.

Today, based in the Bay Area with his wife Shweta and two sons, Sacheth and Sanketh, he continues to remain engaged with science.

There is a certain symmetry in his journey.

A young student who once hoped to treat patients directly now contributes to treatments that reach far beyond individual encounters. A moment defined by two points did not close a path; it transformed it. What began as a void became, over time, a space for something larger to emerge.

In the end, his story is not simply about achievement. It is about resilience, about remaining within a field that demands patience and offers no guarantees. It is about recognizing the role of luck without diminishing the role of effort. And it is about the quiet, enduring belief that even in the most complex systems, it is still possible to create something that changes a life.